Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orally-Disintegrating vs. Regular Olanzapine for Weight Gain in Bipolar Depression
NCT00384332Phase 4Completed
- Sponsor
- Vanderbilt University
- Start
- Jan 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olanzapine in bipolar disorder (BD) (2 arms), sponsored by Vanderbilt University. Primary endpoint: Weight at 8 weeks. Started Jan 2007; status: completed.
02
Drugs
olanzapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00384332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384332.